Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Common Equity (2020 - 2025)

BioAtla (BCAB) has 6 years of Common Equity data on record, last reported at -$31.2 million in Q3 2025.

  • For Q3 2025, Common Equity fell 236.0% year-over-year to -$31.2 million; the TTM value through Sep 2025 reached -$31.2 million, down 236.0%, while the annual FY2024 figure was $14.3 million, 79.82% down from the prior year.
  • Common Equity reached -$31.2 million in Q3 2025 per BCAB's latest filing, down from -$16.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $230.7 million in Q3 2021 and bottomed at -$31.2 million in Q3 2025.
  • Average Common Equity over 5 years is $105.8 million, with a median of $124.5 million recorded in 2023.
  • Peak YoY movement for Common Equity: skyrocketed 440.04% in 2021, then tumbled 236.0% in 2025.
  • A 5-year view of Common Equity shows it stood at $210.8 million in 2021, then decreased by 14.46% to $180.3 million in 2022, then plummeted by 60.81% to $70.7 million in 2023, then tumbled by 79.82% to $14.3 million in 2024, then plummeted by 318.98% to -$31.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Common Equity were -$31.2 million in Q3 2025, -$16.7 million in Q2 2025, and $547000.0 in Q1 2025.